Coursera enters the third quarter as a structurally different operating entity. The Udemy combination closed in mid-May, with management raising both the synergy target and the full-year revenue guide within seven weeks. The Q2 print delivered revenue of $298.6M. The Udemy contribution accounted for $103.8M of the delta, while integration costs of $79.8M absorbed most of the non-GAAP earnings power. Adjusted EBITDA margin expanded 470 bps to 14.3%. The board authorized $500M of buybacks, with $140M completed to date. The transaction shifts the franchise from a single-platform MOOC into a multi-segment skills-development operator with content from more than 350 university partners and the combined Udemy consumer and business libraries underneath a single billing and analytics layer.
The investment debate sits on three variables and the disclosure cadence over the back half of 2026 carries the central evidence stream. Integration execution is the first, with at least $85M of annual run-rate net synergies targeted by year-end. Reported Q2 merger costs reached $79.8M, with integration cash payments adding further pressure on the GAAP P&L. Enterprise renewal is the second variable, where the combined Net Retention Rate of 91% sits 400 bps below the standalone rate reported a year ago. Capital allocation is the third, with $90.3M of buybacks executed at an average price of $5.45 per share. The setup is asymmetric for patient capital willing to underwrite integration risk. The Q2 release also confirmed a $100M strategic investment in LearnVector that anchors the AI-native thesis, with related-party framing and a non-consolidated reporting structure.
The equity trades in the mid-$6 area against a fifty-two week range starting near $5.0. The high end of that range reaches $12.3 per share, with a market capitalization near $1.72B. Enterprise value stands around $643M after netting cash plus marketable securities. That multiple sits below historical averages for the franchise, and below the consensus analyst target of $8.17. Multiple compression against a rising Adjusted EBITDA run-rate is the central setup, with the synergy realization pace and Enterprise renewal trajectory carrying the equity narrative. The valuation discount is wider than the underlying margin trajectory would imply on a normalized basis, which is the source of the asymmetry that patient capital is being asked to underwrite.